Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.

Hamester F, Legler K, Wichert B, Kelle N, Eylmann K, Rossberg M, Ding Y, Kürti S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L.

Br J Cancer. 2019 Oct 29. doi: 10.1038/s41416-019-0607-2. [Epub ahead of print]

PMID:
31659304
2.

Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

Banys-Paluchowski M, Milde-Langosch K, Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B, Müller V.

Breast Cancer Res Treat. 2019 Oct 23. doi: 10.1007/s10549-019-05474-8. [Epub ahead of print]

PMID:
31646390
3.

A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.

Kind S, Jaretzke A, Büscheck F, Möller K, Dum D, Höflmayer D, Hinsch A, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Simon R, Wilczak W, Lebok P, Witzel I, Müller V, Schmalfeldt B, Paluchowski P, Wilke C, Heilenkötter U, von Leffern I, Krech T, Krech RH, von der Assen A, Bawahab AA, Burandt E.

Mol Carcinog. 2019 Dec;58(12):2306-2315. doi: 10.1002/mc.23119. Epub 2019 Sep 23.

PMID:
31545001
4.

Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.

Lebok P, von Hassel A, Meiners J, Hube-Magg C, Simon R, Höflmayer D, Hinsch A, Dum D, Fraune C, Göbel C, Möller K, Sauter G, Jacobsen F, Büscheck F, Prien K, Krech T, Krech RH, von der Assen A, Wölber L, Witzel I, Schmalfeldt B, Geist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt EC.

Aging (Albany NY). 2019 Sep 18;11(18):7796-7804. doi: 10.18632/aging.102287. Epub 2019 Sep 18.

5.

Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2019 Sep 16. pii: clincanres.1741.2019. doi: 10.1158/1078-0432.CCR-19-1741. [Epub ahead of print]

PMID:
31527166
6.

Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.

Klapdor R, Wölber L, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Hillemanns P, Fürst ST, Mahner S.

Gynecol Oncol. 2019 Sep;154(3):565-570. doi: 10.1016/j.ygyno.2019.06.013. Epub 2019 Jun 18.

PMID:
31227222
7.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
8.

Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions.

Grimm D, Woelber L, Prieske K, Schmalfeldt B, Kürti S, Busch CJ, Teudt I, Brummer O, Mueller V, Meyer T.

Eur J Microbiol Immunol (Bp). 2018 Dec 12;8(4):107-111. doi: 10.1556/1886.2018.00018. eCollection 2018 Dec 23.

9.

Superficially invasive stage IA vulvar squamous cell carcinoma-therapy and prognosis.

Grimm D, Prieske K, Mathey S, Kuerti S, Burandt E, Schmalfeldt B, Woelber L.

Int J Gynecol Cancer. 2019 Mar;29(3):466-473. doi: 10.1136/ijgc-2018-000046. Epub 2019 Jan 4.

PMID:
30622111
10.

A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.

Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW.

Biomaterials. 2019 Jan;190-191:63-75. doi: 10.1016/j.biomaterials.2018.10.014. Epub 2018 Oct 16.

PMID:
30396040
11.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
12.

Participation of elderly gynecological cancer patients in clinical trials.

Prieske K, Trillsch F, Oskay-Özcelik G, Chekerov R, Bleich C, Oliveira-Ferrer L, Grimm D, Kuerti S, Mueller V, Suling A, Schmalfeldt B, Sehouli J, Mahner S, Woelber L.

Arch Gynecol Obstet. 2018 Oct;298(4):797-804. doi: 10.1007/s00404-018-4886-2. Epub 2018 Aug 30.

PMID:
30167853
13.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
14.

Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.

Oliveira-Ferrer L, Goswami R, Galatenko V, Ding Y, Eylmann K, Legler K, Kürti S, Schmalfeldt B, Milde-Langosch K.

Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.

15.

Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer.

Wichert B, Milde-Langosch K, Galatenko V, Schmalfeldt B, Oliveira-Ferrer L.

Glycobiology. 2018 Nov 1;28(11):898-903. doi: 10.1093/glycob/cwy065.

PMID:
30016515
16.

Correlation of Isotope Count With Sentinel Node Positivity in Vulvar Cancer.

Woelber L, Joosse SA, Grimm D, Mathey S, Mahner S, Burandt E, Klutmann S, Schmalfeldt B, Prieske K.

Int J Gynecol Cancer. 2018 Sep;28(7):1403-1409. doi: 10.1097/IGC.0000000000001298.

PMID:
29923853
17.

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.

Legler K, Rosprim R, Karius T, Eylmann K, Rossberg M, Wirtz RM, Müller V, Witzel I, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L.

Br J Cancer. 2018 Mar 20;118(6):847-856. doi: 10.1038/bjc.2017.472. Epub 2018 Jan 30.

18.

Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.

Avril S, Dincer Y, Malinowsky K, Wolff C, Gündisch S, Hapfelmeier A, Boxberg M, Bronger H, Becker KF, Schmalfeldt B.

Oncotarget. 2017 Jun 8;8(58):97851-97861. doi: 10.18632/oncotarget.18415. eCollection 2017 Nov 17.

19.

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.

Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.

Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.

20.

[Current Status of Targeted Treatment in Breast Cancer].

Seiffert K, Schmalfeldt B, Müller V.

Dtsch Med Wochenschr. 2017 Nov;142(22):1669-1675. doi: 10.1055/s-0043-108468. Epub 2017 Oct 27. German.

PMID:
29078212
21.

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA, Dörk T, Edwards R, deFazio A, Friel G, Goodman MT, Hillemanns P, Høgdall E, Jensen A, Jordan SJ, Karlan BY, Kjær SK, Klapdor R, Matsuo K, Mizuno M, Nagle CM, Odunsi K, Paddock L, Rossing MA, Schildkraut JM, Schmalfeldt B, Segal BH, Starbuck K, Terry KL, Webb PM, Zsiros E, Ness RB, Modugno F, Bandera EV, Chang-Claude J, Moysich KB.

Br J Cancer. 2017 Sep 26;117(7):1063-1069. doi: 10.1038/bjc.2017.267. Epub 2017 Aug 17.

22.

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients.

Kuerti S, Oliveira-Ferrer L, Milde-Langosch K, Schmalfeldt B, Legler K, Woelber L, Prieske K, Mahner S, Trillsch F.

Oncotarget. 2017 Jun 27;8(26):43218-43227. doi: 10.18632/oncotarget.17978.

23.

CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.

Windmüller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M, Bronger H.

Oncogenesis. 2017 May 15;6(5):e331. doi: 10.1038/oncsis.2017.29.

24.

Oral Human Papillomavirus in Women With High-Grade Cervical Intraepithelial Neoplasia.

Woelber L, Breuer J, Meyer T, Vettorazzi E, Prieske K, Bohlmann I, Busch CJ, Teudt I, Brummer O, Mueller V, Schmalfeldt B, Grimm D.

J Low Genit Tract Dis. 2017 Jul;21(3):177-183. doi: 10.1097/LGT.0000000000000313.

PMID:
28481782
25.

The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review.

Buhling KJ, Lezon S, Eulenburg C, Schmalfeldt B.

Arch Gynecol Obstet. 2017 May;295(5):1259-1268. doi: 10.1007/s00404-017-4346-4. Epub 2017 Mar 29. Review.

PMID:
28357559
26.

Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience.

Jendrian S, Steffens K, Schmalfeldt B, Laakmann E, Bergelt C, Witzel I.

Breast Cancer Res Treat. 2017 Jun;163(3):517-526. doi: 10.1007/s10549-017-4208-6. Epub 2017 Mar 21.

PMID:
28324266
27.

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, Odunsi K, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dӧrk T, Hillemanns P, Kelemen LE, Kӧbel M, Steed H, de Fazio A; Australian Ovarian Cancer Study Group, Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB; Ovarian Cancer Association Consortium.

Cancer Causes Control. 2017 May;28(5):469-486. doi: 10.1007/s10552-017-0867-1. Epub 2017 Mar 14.

28.

Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.

Witzel I, Marx AK, Müller V, Wikman H, Matschke J, Schumacher U, Stürken C, Prehm P, Laakmann E, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L.

Breast Cancer Res Treat. 2017 Apr;162(3):427-438. doi: 10.1007/s10549-017-4135-6. Epub 2017 Feb 6.

PMID:
28168629
29.

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study.

Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S.

Ann Surg Oncol. 2017 May;24(5):1314-1321. doi: 10.1245/s10434-016-5687-0. Epub 2016 Nov 28.

PMID:
27896515
30.

Sarcopenia in Advanced Serous Ovarian Cancer.

Bronger H, Hederich P, Hapfelmeier A, Metz S, Noël PB, Kiechle M, Schmalfeldt B.

Int J Gynecol Cancer. 2017 Feb;27(2):223-232. doi: 10.1097/IGC.0000000000000867.

PMID:
27870708
31.

Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study.

Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann KH, Thiel FC, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S.

Eur J Cancer. 2016 Dec;69:180-188. doi: 10.1016/j.ejca.2016.09.038. Epub 2016 Nov 10.

PMID:
27837710
32.

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.

Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E.

Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227.

33.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

34.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48].

Claussen C, Rausch AV, Lezius S, Amirkhosravi A, Davila M, Francis JL, Hisada YM, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F.

Thromb Res. 2016 Oct;146:135. doi: 10.1016/j.thromres.2016.09.008. Epub 2016 Sep 16. No abstract available.

PMID:
27640329
35.

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S.

Br J Cancer. 2016 Aug 23;115(5):553-63. doi: 10.1038/bjc.2016.172. Epub 2016 Aug 4.

36.

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S.

Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27468640
37.

Patterns of distant metastases in vulvar cancer.

Prieske K, Haeringer N, Grimm D, Trillsch F, Eulenburg C, Burandt E, Schmalfeldt B, Mahner S, Mueller V, Woelber L.

Gynecol Oncol. 2016 Sep;142(3):427-34. doi: 10.1016/j.ygyno.2016.07.009. Epub 2016 Jul 9.

PMID:
27401841
38.

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.

Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB.

Br J Cancer. 2016 Jun 28;115(1):95-101. doi: 10.1038/bjc.2016.153. Epub 2016 Jun 14.

39.

Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.

Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Brian Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva AN, Zirpoli GR, Bandera EV, Berchuck A, Cramer D, Doherty JA, Edwards RP, Fridley BL, Goode EL, Goodman MT, Hogdall E, Hosono S, Jensen A, Jordan S; Australian Ovarian Cancer Study Group, Kjaer SK, Matsuo K, Ness RB, Olsen CM, Olson SH, Leigh Pearce C, Pike MC, Anne Rossing M, Szamreta EA, Thompson PJ, Tseng CC, Vierkant RA, Webb PM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Schildkraut JM, Terry KL, Kelemen LE, Moysich KB.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1114-24. doi: 10.1158/1055-9965.EPI-15-1330. Epub 2016 May 6. Review.

40.

Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.

Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E, Schmalfeldt B, Loessner D, Kotzsch M, Magdolen V.

Am J Cancer Res. 2015 Dec 15;6(1):61-70. eCollection 2016.

41.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.

Claussen C, Rausch AV, Lezius S, Amirkhosravi A, Davila M, Francis JL, Hisada YM, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F.

Thromb Res. 2016 May;141:39-48. doi: 10.1016/j.thromres.2016.03.002. Epub 2016 Mar 2. Erratum in: Thromb Res. 2016 Oct;146:135.

PMID:
26967531
42.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K.

Ann Surg Oncol. 2016 Aug;23(8):2508-14. doi: 10.1245/s10434-016-5114-6. Epub 2016 Feb 8.

PMID:
26856721
43.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28.

PMID:
26731724
44.

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.

Br J Clin Pharmacol. 2015 Nov;80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22.

45.

Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J; Kommission Ovar of the Gynecologic Oncology Study Group (AGO).

Geburtshilfe Frauenheilkd. 2015 Apr;75(4):339-341. No abstract available.

46.

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.

Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators.

Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476.

PMID:
25978292
47.

Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J.

Arch Gynecol Obstet. 2015 Jul;292(1):231-4. doi: 10.1007/s00404-015-3697-y. Epub 2015 Apr 26. Review.

PMID:
25914073
48.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.

Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A.

Br J Cancer. 2015 Feb 17;112(4):660-6. doi: 10.1038/bjc.2014.648. Epub 2015 Jan 6.

49.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25481791
50.

OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery.

Dorn J, Bronger H, Kates R, Slotta-Huspenina J, Schmalfeldt B, Kiechle M, Diamandis EP, Soosaipillai A, Schmitt M, Harbeck N.

Oncol Lett. 2015 Jan;9(1):418-424. Epub 2014 Oct 24.

Supplemental Content

Loading ...
Support Center